Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Nederlands Vaccin Instituut (NVI) was a Dutch government-owned organization dedicated to the research, development, and production of vaccines for the National Immunisation Programme. Based in Bilthoven, the institute played a critical role in public health by ensuring the supply of essential vaccines against diseases such as polio, diphtheria, and pertussis. In 2012, the Dutch government privatized the NVI's vaccine production and development activities, selling them to the Serum Institute of India, which subsequently established Bilthoven Biologicals. The public health policy and procurement functions were integrated into the National Institute for Public Health and the Environment (RIVM). The NVI was particularly noted for its expertise in inactivated polio vaccine (IPV) technology and its contributions to global eradication efforts. Its facilities were equipped for large-scale GMP manufacturing of biologics, serving both domestic and international markets through partnerships with organizations like WHO and UNICEF.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nederlands Vaccin Instituut.